Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Article in Press
Brief Report
Case Report
Case Report and Review
Case Reports
Case Series
Commentary
Editorial
Erratum
How do I do it
How I do it?
Invited Editorial
Letter to Editor
Letter to Editor/Case Reports/Images
Letter to the Editor
Letters to Editor
Letters to the Editor
Mini Review
Original Article
Original Articles
Original Research
Other Type
Others
Review Article
Short Paper
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Article in Press
Brief Report
Case Report
Case Report and Review
Case Reports
Case Series
Commentary
Editorial
Erratum
How do I do it
How I do it?
Invited Editorial
Letter to Editor
Letter to Editor/Case Reports/Images
Letter to the Editor
Letters to Editor
Letters to the Editor
Mini Review
Original Article
Original Articles
Original Research
Other Type
Others
Review Article
Short Paper
View/Download PDF

Translate this page into:

Original Article
12 (
1
); 27-31
doi:
10.1055/s-0040-1713687

Spectrum of Aminoglycoside Modifying Enzymes in Gram-Negative Bacteria Causing Human Infections

Department of Microbiology, Sri Ramachandra Institute for Higher Education and Research, Chennai, Tamil Nadu, India
Address for correspondence Aishwarya KVL, MSc, Department of Microbiology, Sri Ramachandra Institute for Higher Education and Research, Porur, Chennai 600116, Tamil Nadu, India (e-mail: mailaishmicro@gmail.com).
Licence
This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0
Disclaimer:
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Introduction

Aminoglycosides are formidable broad-spectrum antibiotics used in clinical settings; woefully their usage has been reduced by the emergence and distribution of resistance mainly due to aminoglycoside modifying enzymes (AME).

Purpose

This study was performed to determine the diverse prevalence of AME and their pattern of occurrence in the clinical isolates of gram-negative bacteria. This study also aimed to detect the presence of AMEs that are prevalent in gram-positive bacteria, among gram negatives.

Materials and Methods

A total number of 386 clinical isolates were included in this study. Polymerase chain reaction revealed the prevalence rate of AMEs screened [aac(6′)-lb, aac(3′)-I, aac(3′)-II, aac(3′)-VI, ant(2′)-I, ant(4′)-IIb, aac(3′)-III, aac(3′)-IV, aph(2′)-Ib, aph(2′)-Ic, aph(2′)-Id, aac (6′)-Ie- aph(2′)-Ia, and aph(3′)-IIIa]. Conjugation experiment was performed for the clinical isolates which harbored any one of the AME which was prevalent in gram-positive bacteria [aph(3′)-IIIa, aac(6′)-Ie-aph(2′)-Ia].

Results

aac(6′)-lb is the most prevalent AME, followed by aac(3′)-I, aph(3′)-VI, aac(3′)-VI, and aac(3′)-II. The AMEs such as ant (2′)-I, ant(4′)-IIb, aac(3′)-III, aac(3′)-IV, aph(2′)-Ib, aph(2′)-Ic, and aph(2′)-Id were not established in our study isolates. The rate of prevalence of aph(3′)-IIIa, aac(6′)-Ie-aph(2′)-Ia—the AMEs encountered in gram-positive and their co-existence was 19.68% and the conjugation experiment revealed their transfer via plasmids.

Conclusion

This is the first report from India revealing the presence and prevalence of AMEs which are often encountered among gram-positive bacteria in gram negatives and their presence on conjugative plasmids.

Keywords

AME
conjugative plasmid
GP AME
gram-negative bacteria

Introduction

Aminoglycosides (AG) play an important and adjunctive role in the treatment of life-threatening infections owing to their synergetic and broad-spectrum activity against both gram-positive and gram-negative bacteria. This group of antibiotics bind to the ribosomes of the bacteria thereby leading to inhibition of protein synthesis and consequent bacterial cell death. Their extensive use has resulted in development and dissemination of resistance to this class of antimicrobials.

The mechanisms of aminoglycoside resistance are diverse. The most common mechanism is the inactivation of the antibiotic by a family of enzymes named aminoglycoside modifying enzymes (AME).1 The AMEs catalyze the modification of the AGs at–OH or–NH2 groups of the 2-deoxystreptamine nucleus or sugar moieties via acetyltransferases, nucleotidyltransferases, and phosphotransferases2 which modify the drug, resulting in poor binding to the ribosome thereby allowing the bacteria to survive in the presence of the drug.3

Besides the AMEs, other resistance mechanisms include change in bacterial membrane permeability, expression of efflux pumps, and methylation through 16S ribosomal RNA methyltransferases. These 16S rRNA methyltransferases are often encountered in multidrug-resistance gram negatives especially among New Delhi Metallo betalactamase producers.4

There are more than 85 AMEs reported in both gram-positive and gram-negative bacteria. A few among them, particularly ant(2′)-I, aac(6′)-I, aac(3′)-I to IV, and aac(3′)-VI, undergo continuous mutation5 leading to the generation of new AME variants which utilize a variety of AGs as substrates, cleave them, and make them ineffective. These AMEs virtually spread to all bacterial types through conjugative plasmids, natural transformation, or transduction.6

Dissemination of AMEs via plasmids has been reported in developed countries.7 Since there is a paucity of information from India regarding the prevalence and type of AMEs in gram-negative bacteria, the present study was undertaken to determine their prevalence among clinical isolates of gram-negative bacteria in a tertiary care center.

There are some AMEs which were originally detected in gram-positive (GP AMEs) bacteria and characteristically occur in them. They are aph(3′)-IIIa that is the most prevalent and a bifunctional AME aac(6′)-Ie-aph(2′)-Ia. They confer resistance to a broad spectrum of AGs. There have been reports of their presence in gram-negative clinical isolates from Slovakia and Germany.8 Hence, this study was aimed to detect their presence in gram-negative bacteria.

Materials and Methods

Ethical Approval

The study was approved by the Institutional Ethical Committee (IEC-NI/15/APR/6/18).

Bacterial Isolates

A total of 386 amikacin-resistant gram-negative bacteria which were clinically significant and nonduplicate were collected over a period of 3 years from June 2015 to September 2018. All the isolates were speciated based on conventional or VITEK-2 system (Vitek-2 GN-card; BioMerieux).The bacterial isolates included were obtained from different clinical sources such as blood (14), urine (176), exudate (162), and respiratory secretion s(34)

Antibiotic Susceptibility Testing

Disk diffusion test was performed in accordance with the Clinical Laboratory Standard Institute (CLSI, 2016).9 The AGs tested were amikacin (30 µg), gentamicin (10 µg), tobramycin (10 µg), and netilmicin (10 µg) (HiMedia Laboratories).

Polymerase Chain Reaction

Nine sets of uniplex and two sets of multiplex polymerase chain reactions (PCRs) were performed for AMEs using previously described primers and conditions.10-14 The primers used for different sets of genes, their annealing temperatures, and the amplicon sizes are listed in Table 1.

Table 1 Primers used for performing PCR for amplifying AME genes
Simplex set Gene Primer Annealing temperature (°C) Amplicon size (bp)
1 aac(6′)-lb F-TTG CGA TGC TCT ATG AGT GGC TA R-CTC GAA TGC CTG GCG TGT TT 60 482
2 aph(3′)-VI F-ATGGAATTGCCCAATATTATT R-TCAATTCAATTCATCAAGTTT 55 780
3 aac(3′)-I F-TTC ATC GCG CTT GCT GCY TTY R-GC CAC TGC GGG ATC GTC RCC RTA 56 239
4 aac(3′)-II F-GCG CAC CCC GAT GCM TCS ATG G R-GGC AAC GGC CTC GGC GTA RTG SA 58 370
5 aac(3′)-III F-GAC AAT GGC GTG CTA SCS GAR T R-C CAG ATG CTC GGC ATG RTG SAG 58 241
6 aac(3′)-IV F-GAC GAC GAG CCG TTC GAY CC R-C CT CAA CTC GGC AAG ATG SAG 58 280
7 aac(3′)-VI F-GCC CT CCC GAC GCA TCS ATG G R-CGC CAC CGC TTC GGC ATA RTG SA 55 780
8 ant(2′)-I F-TGG GCG ATC GAT GCA CGG CTR G R-AA AGC GGC ACG CAA GAC CTC MAC 58 428
9 ant(4′)-IIb F TAT CTC GGC GGT CGA GT R CAC GCG GGG AAA CGC GAG AA 60 364
Multiple × 1 aac(6′)-Ie-aph(2′)-Ia F-CAGGAATTTATCGAAAATGGTAGAAAAG R-CACAATCGACTAAAGAGTACCAATC 55 369
aph(3′)-IIIa F-GGCTAAAATGAGAATATCACCGG R-CTTTAAAAAATCATACAGCTCGCG 523
Multiple × 2 aph(2′)-Ib F-CTTGGACGCTGAGATATATGAGCAC R-GTTTGTAGCAATTCAGAAACACCCTT 58 867
aph(2′)-Ic F-CCACAATGATAATGACTCAGTTCCC R-CCACAGCTTCCGATAGCAAGAG 444
aph(2′)-Id F-GTGGTTTTTACAGGAATGCCATC R-CCCTCTTCATACCAATCCATATAACC 641

Abbreviations: AME, aminoglycoside modifying enzymes; PCR, polymerase chain reaction.

Seven sets of uniplex PCRs were performed for 16SrRNA methyltransferase using primers established in our earlier study.15

Each reaction volume contained 2 µL of the deoxyribonucleic acid (DNA) template added to the master mix which includes 10 pmol of the forward and reverse primers (Sigma-Aldrich), 10 mm deoxyribonucleotide triphosphate (Takara), 5U Taq polymerase (Takara), and 10× buffer with MgCl2 (Takara).

Amplification of the reactions was performed under the following conditions: initial denaturation at 95°C for 4 minutes, followed by 32 cycles of denaturation at 94°C for 30 seconds, annealing based on the primer employed for 30 seconds with an extension at 72°C for 50 seconds, and a final extension for one cycle at 72°C for 5 minutes. The PCR product was then run on a 1.5% agarose gel for detection of the amplified fragment.

Template DNA Preparation

A single bacterial colony was inoculated into Luria-Bertani broth (HiMedia Laboratories) and incubated overnight at 37°C, and it was then centrifuged at 10,000 rpm for 10 minutes. The pellet was re-suspended in 250 µL of Millipore water, boiled at 100°C for 10 minutes, and cooled and centrifuged at 10,000 rpm for 10 minutes. The supernatant served as the template DNA.16

DNA Sequencing

PCR-positive amplicons were purified and sequenced. The sequenced strains served as positive controls. Sequencing was done by BigDye 3.1 cycle sequencing kit using Sanger AB13730 XL DNA analyzing instrument (AgriGenome). The nucleotide sequences were aligned using the Bioedit sequence program (product version 7.0.5.3) and were compared with the basic alignment search tool available at the National Center for Biotechnology Information website (www.ncbi.nIm.nih.gov).

Conjugation Assay

Bacterial conjugation was performed at 37°C for the clinical isolates which harbored either one of the GP AMEs [aph(3′)-IIIa and aac(6′)-Ie-aph(2′)-Ia]. Azide-resistant Escherichia coli J53 served as recipient. The transconjugants were selected on MacConkey agar plate containing 100 μg of sodium azide (HiMedia Laboratories) along with 4 μg of amikacin.17 The transferability of the AMEs through plasmid in transconjugants was confirmed by PCR.

Result

The study isolates includes E. coli (n = 79), Klebsiella pneumonia (n = 149), Klebsiella oxytoca (n = 4), Citrobacter freundii (n = 2), Enterobacter cloacae (n = 11), Proteus mirabilis (n = 5), Proteus vulgaris (n = 2), Providencia rettgeri (n = 16), Morganella morganii (n = 12), Pseudomonas aeruginosa (n = 63), Pseudomonas fluorescens (n = 4), Pseudomonas putida (n = 1), and Acinetobacter baumannii (n = 38). All the study isolates exhibited resistance to all the tested AGs as determined by disk diffusion method.

PCR identification revealed the prevalence of 16SrRNA methyltransferases and AMEs, of which all the clinical isolates carried one or more than one 16SrRNA methyltransferases (data were not disclosed in this study). Of the study isolates, 46.63% harbored single AME and 38.86% harbored more than one AME. The distributions of these enzymes among the different gram-negative species were tabulated (Table 2).

Table 2 Distribution of AME genes and their combination among different gram negatives
Aminoglycoside modifying enzyme genes Total number of gram negatives (n = 386)
E. coli (n = 79) Klebsiella (n = 153) Citrobacter (n = 2) Enterobacter (n = 11) Proteus (n = 7) Providencia (n = 16) Morganella (n = 12) Pseudomonas (n = 68) Acinetobacter (n = 38)
aac(6′)-lb (n = 135) 22 59 2 5 4 4 6 21 12
aac(3′)-I (n = 24) 7 4 1 3 3 1 4 1
aph(3′)-VI (n = 13) 5 1 7
aac(3′)-VI (n = 5) 3 2
aac(3′)-II (n = 3) 3
aac(6′)-lb+ aac(3′)-I(n = 68) 30 24 1 1 10 2
aac(6′)-lb+ aph(3′)-VI (n = 47) 6 24 1 2 7 7
aac(6′)-lb+ aac(3′)-II (n = 8) 3 5
aph(3′)-VI + aac(3′)-I (n = 3) 3
aac(6′)-lb+ aph(3′)-VI + aac(3′)-I (n = 20) 2 7 7 4
aac(6′)-lb+ aac(3′)-I+ aac(3′)-II (n = 1) 1
aac(6′)-lb+ ac(3′)-I+ aac(3′)-II + aph(3′)-VI (n = 3) 3

Abbreviations: AME, aminoglycoside modifying enzymes.

Interestingly GP AMEs namely aph(3′)-IIIa and aac(6′)-Ie- aph(2′)-Ia were identified in this study isolates. They were detected in 3.88 and 8.03% of the study isolates, respectively (Table 3). Co-occurrence of both of these enzymes was encountered in 7.77%.

Table 3 Study isolates associated with AMEs prevalent in gram-positive bacteria
Gram-positive AMEs Total number of gram negatives (n = 386)
E. coli (n = 79) Klebsiella (n = 153) Citrobacter (n = 2) Enterobacter (n = 11) Proteus (n = 7) Providencia (n = 16) Morgonella (n = 12) Pseudomonas (n = 68) Acinetobacter (n = 38)
aph(3′)-IIIa (n = 15) 7 8
aac(6′)-Ie- aph(2′)-Ia (n = 31) 4 5 2 5 2 8 5
aph(3′)-IIIa + aac(6′)-Ie- aph(2′)-Ia (n = 30) 6 13 3 8

Abbreviation: AME, aminoglycoside modifying enzymes.

However, AMEs such as ant(2′)-I, ant(4′)-IIb, aac(3′)-III, aac(3′)-IV, aph(2′)-Ib, aph(2′)-Ic, and aph(2′)-Id were not encountered in any of the study isolates.

Conjugation assay was successful in all the clinical isolates tested which harbored the GP AMEs.

Discussion

AGs play a vital role as monotherapy and in combination for the treatment of majority of bacterial infection. The resistance to AGs in bacteria is predominantly due to the AMEs.1

All the 386 clinical isolates were resistant to all the tested AGs. They did not exhibit any substrate-specific hydrolyzing profile which is commonly encountered in AME. This is attributable to the presence of 16S rRNA methyltransferases which confer resistance to all AGs.4

The prevalence of aac(6′)-lb singly and in combinations with other AME is higher (Table 2) when compared with previous reports from Iran, China, and Spain which had 31. 6, 19.6, 4.2% of aac(6′)-lb, respectively.18-20 The AME aac(3′)-I was the second most prevalent gene singly and in also combination(6.21 and 17.61%). This enzyme has been reported in large number of gram-negative clinical isolates previously.2 The enzyme aph(3′)-VI, first identified in A. baumannii in 1988,21 was the third most prevalent gene.

AMEs such as ant(2′)-I, ant(4′)-IIb, aac(3′)-III, and aac(3′)-IV were not encountered in our study isolates but their presence was widely reported in countries like Iran,22 France23 and China.24 The GP AMEs aph(2′)-Ib, aph(2′)-Ic, and aph(2′)-Id were not encountered in our study; however, their presence was significantly reported in Enterococci and Staphylococcus.14,25 This significant difference in their presence of AMEs may be due to usage of antibiotics and other geographical factors involved.19

The bifunctional enzyme aac(6′)-Ie-aph(2′)-Ia that confers high-level resistance to gentamicin, amikacin, tobramycin, netilmicin and is considered more prevalent in Enterococci26 has been identified in the present study; there are two previous reports citing its presence and transferability in gram-negative bacteria.8 The prevalence of these AMEs in this study is 19.68% and their transfer indicates their location on conjugative plasmids. However, the prevalence rate is significantly less compared with their rate of occurrence in Enterococci (38.20%).27

Conclusion

Our findings throw light on the distribution of the different AMEs and their combination among the clinical isolates of gram-negative bacteria. To the best of our knowledge, this is the first report to study the presence of GP AMEs in gram-negative bacteria from India. Considering the transferability potential of these resistance genes between gram-positive and gram-negative bacteria frequent surveillance studies are required to study the changing pattern and evolution of resistance among bacteria.

Conflict of Interest

None.

Reference

  1. , . Emergence of rmtC and rmtF 16S rRNA methyltransferase in clinical isolates of Pseudomonas aeruginosa. In: Indian J Med Microbiol. Vol 35. . p. :282-285.
    [CrossRef] [PubMed] [Google Scholar]
  2. , . Aminoglycoside modifying enzymes. Drug Resist Updat. 2010;13(06):151-171.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , . Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev. 1993;57(01):138-163.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , . Updated multiplex polymerase chain reaction for detection of 16S rRNA methylases: high prevalence among NDM-1 producers. Diagn Microbiol Infect Dis. 2011;71(04):442-445.
    [CrossRef] [PubMed] [Google Scholar]
  5. , . Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003;16(03):430-450.
    [CrossRef] [PubMed] [Google Scholar]
  6. . Overview of dissemination mechanisms of genes coding for resistance to antibiotics. In: , , eds. Enzyme-Mediated Resistance to Antibiotics: Mechanisms, Dissemination, and Prospects for Inhibition. Washington, DC: ASM Press; . p. :267-270.
    [Google Scholar]
  7. , . Resistance due to aminoglycoside modifying enzymes in Pseudomonas aeruginosa isolates from burns patients. Indian J Med Res. 2005;122(04):324-329.
    [Google Scholar]
  8. , , , , , . Transferable amikacin resistance in gram-negative bacterial isolates. Chemotherapy. 1995;41(03):187-192. [AP6]
    [CrossRef] [PubMed] [Google Scholar]
  9. . Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100S. In: CLSI Supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; .
    [Google Scholar]
  10. , , , et al.. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother. 2012;24(04):191-194.
    [CrossRef] [PubMed] [Google Scholar]
  11. , , . Norwegian Study Group on Aminoglycoside Resistance. Increased prevalence of aminoglycoside resistance in clinical isolates of Escherichia Coli and Klebsiella Spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6’)-Ib. Diagn Microbiol Infect Dis. 2014;78(01):66-69.
    [CrossRef] [PubMed] [Google Scholar]
  12. , , , , . High-level amikacin resistance inassociated with a 3′-phosphotransferase with high affinity for amikacin. Pseudomonas aeruginosa. Int J Antimicrob Agents. 2000;15(04):257-263.
    [CrossRef] [PubMed] [Google Scholar]
  13. , , , . et al. Gentamicin resistance genes in environmental bacteria: prevalence and transfer. FEMS Microbiol Ecol. 2002;42(02):289-302.
    [CrossRef] [PubMed] [Google Scholar]
  14. , , , , , . Multiplex PCR for detection of aminoglycoside resistance genes in Enterococci. Antimicrob Agents Chemother. 2003;47(04):1423-1426.
    [CrossRef] [PubMed] [Google Scholar]
  15. , . , , . Co-occurrence of two 16S rRNA methyltransferases along with NDM and OXA 48 like carbapenamases on a single plasmid in Klebsiella pneumoniae. J Lab Physicians. 2019;11(04):305-311.
    [CrossRef] [PubMed] [Google Scholar]
  16. , . Detection of plasmid-mediated AmpCβ-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol. 2002;40(06):2153-2162.
    [CrossRef] [PubMed] [Google Scholar]
  17. , , , et al.. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents. 2010;35(03):227-234.
    [CrossRef] [PubMed] [Google Scholar]
  18. , , , , . Dissemination of genes encoding aminoglycoside-modifying enzymes and arm A amongisolates in Northwest Iran. Enterobacteriaceae Microb Drug Resist. 2017;23(07):826-832.
    [CrossRef] [PubMed] [Google Scholar]
  19. , , , et al.. A high throughput multiplex PCR assay for simultaneous detection of seven aminoglycoside-resistance genes in Enterobacteriaceae. BMC Microbiol. 2013;13(01):58.
    [CrossRef] [PubMed] [Google Scholar]
  20. , , , . et al. Characterization of aminoglycoside-modifying enzymes in Enterobacteriaceae clinical strains and characterization of the plasmids implicated in their diffusion. Microb Drug Resist. 2013;19(02):94-99.
    [CrossRef] [PubMed] [Google Scholar]
  21. , , . Nucleotide sequence of Acinetobacter baumannii aphA-6 gene: evolutionary and functional implications of sequence homologies with nucleotide-binding proteins, kinases and other aminoglycoside-modifying enzymes. Mol Microbiol. 1988;2(05):615-625.
    [CrossRef] [PubMed] [Google Scholar]
  22. , , , , . Evaluating the frequency of aac (6′)-IIa, ant (2′′)-I, intl1, and intl2 genes in aminoglycosides resistantisolates obtained from hospitalized patients in Yazd, Iran. Klebsiella pneumoniae Avicenna J Med Biotechnol. 2018;10(02):115-119.
    [Google Scholar]
  23. , , , et al.. Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres) J Antimicrob Chemother. 2008;62(02):316-323.
    [CrossRef] [PubMed] [Google Scholar]
  24. , , . Resistance patterns and detection of aac(3′)-IV gene in apramycin-resistant Escherichia coli isolated from farm animals and farm workers in northeastern of China. Res Vet Sci. 2009;87(03):449-454.
    [CrossRef] [PubMed] [Google Scholar]
  25. , , , et al.. Detection of the high-level aminoglycoside resistance gene aph(2”)-Ib in Enterococcus faecium. Antimicrob Agents Chemother. 2000;44(10):2876-2879.
    [CrossRef] [PubMed] [Google Scholar]
  26. , , , , . Prevalence of aac(6′)-Ie-aph(2′′)-Ia resistance gene and its linkage to Tn5281 in Enterococcus faecalis and Enterococcus faecium isolates from Tabriz hospitals. Iran J Microbiol. 2013;5(03):203-208.
    [Google Scholar]
  27. , , . High level aminoglycoside resistance and distribution of aminoglycoside resistant genes among clinical isolates ofspecies in Chennai, India. Enterococcus Scientific World Journal. 2014;2014 329157
    [CrossRef] [PubMed] [Google Scholar]
Show Sections